Background
Patients and methods
Study design
Evaluation of outcomes
Transcriptomic analysis
Statistical analysis
Results
Patients' characteristics and outcomes
Patient characteristics | Anti-PD1 + Cetirizine (n = 71) n (%) | Anti-PD1 alone n = 50, n (%) |
---|---|---|
Age (years), mean (range) | 61 (27–90) | 64 (38–91) |
Gender (female/male) | 30 (42.3)/41 (57.7) | 23 (43.8)/27 (56.2) |
Melanoma AJCC VII stage | ||
• Stage IV | 67 (94.4) | 47 (94.0) |
• Stage IIIC | 3 (4.2) | 2 (4.0) |
• Stage IIIB | 1 (1.4) | 1 (2.0) |
CNS metastases at baseline | 14 (19.7) | 14 (28.0) |
BRAF status | ||
• Wild-type | 56 (78.9) | 35 (70.0) |
• Mutation | 10 (14.1) | 12 (24.0) |
• NA | 5 (7.0) | 3 (6.0) |
Type of anti-PD-1 agent | ||
• Pembrolizumab | 25 (35.2) | 18 (36.0) |
• Nivolumab | 46 (64.8) | 32 (64.0) |
Line of treatment (anti-PD-1) | ||
• First-line treatment | 49 (69.0) | 39 (78.0) |
• Second-line treatment | 22 (31.0) | 11 (22.0) |
Type of previous therapy | ||
• Ipilimumab | 22 (100) | 11 (100) |
Response rate at first assessment | ||
• Complete response | 8 (11.3) | 3 (6.0) |
• Partial response | 16 (22.5) | 8 (16.0) |
• Stable disease | 24 (33.8) | 9 (18.0) |
• Progression disease | 23 (32.4) | 30 (60.0) |
ECOG PS | ||
• 0/1 | 63 (88.7) | 40 (80.0) |
• > 2 | 8 (11.3) | 10 (20.0) |
Allergic patients | 4 (5.7) | 5 (10.0) |
Drugs related allergies | 3 (4.2) | 4 (8.0) |
Sseasonal allergies | 1 (1.4) | 1 (2.0) |
Median OS (months) | 27.59 | 19.30 |
Median PFS (months) | 18.05 | 10.02 |
M category | ||
• M0 | 4 (5.6) | 2 (4.0) |
• M1a | 9 (12.7) | 7 (14) |
• M1b | 9 (12.7) | 7 (14.0) |
• M1c | 49 (69.0) | 34 (68.0) |
LDH | ||
• High | 22 (31.0) | 17 (34.0) |
• Normal | 25 (35.2) | 23 (46) |
• NA | 24 (33.8) | 10 (20) |
Covariate | Multivariate analysis | Univariate analysis | ||||
---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | |
PFS | ||||||
BRAF mut | 1.635 | 0.9208 to 2.9015 | 0.0933 | 1.495 | 0.8725 to 2.5603 | 0.1434 |
CNS mtx | 1.951 | 1.0940 to 3.4790 | 0.0235 | 2.159 | 1.3161 to 3.5423 | 0.0023 |
ECOG PS | 4.859 | 2.2453 to 10.5135 | 0.0001 | 6.041 | 2.9530 to 12.3593 | < 0.0001 |
Gender | 1.418 | 0.8056 to 2.4967 | 0.2259 | 1.305 | 0.8221 to 2.0721 | 0.2587 |
LDH | 2.058 | 1.2155 to 3.4841 | 0.0072 | 1.635 | 1.0384 to 2.5740 | 0.0338 |
M category | 0.95 | 0.7188 to 1.2554 | 0.7179 | 0.785 | 0.6030 to 1.0223 | 0.0725 |
Anti-H treatment | 0.595 | 0.3596 to 0.9853 | 0.0436 | 0.545 | 0.3467 to 0.8566 | 0.0085 |
OS | ||||||
BRAF mut | 1.098 | 0.5510 to 2.1861 | 0.7913 | 1.066 | 0.5697 to 1.9959 | 0.8409 |
CNS mtx | 1.647 | 0.8473 to 3.1998 | 0.1412 | 2.27 | 1.2923 to 3.9859 | 0.0043 |
ECOG PS | 2.751 | 1.2144 to 6.2326 | 0.0153 | 4.487 | 2.2537 to 8.9347 | < 0.0001 |
Gender | 1.943 | 0.9641 to 3.9145 | 0.0632 | 1.426 | 0.8069 to 2.5196 | 0.2219 |
LDH | 2.979 | 1.5411 to 5.7585 | 0.0012 | 1.851 | 1.0747 to 3.1873 | 0.0264 |
M category | 0.794 | 0.5298 to 1.1906 | 0.2646 | 0.634 | 0.4236 to 0.9483 | 0.0265 |
Anti-H treatment | 0.392 | 0.2092 to 0.7328 | 0.0034 | 0.404 | 0.2340 to 0.6987 | 0.0012 |